"As part of the integration of Barr and PLIVA, we met our short-term
goals of completing the global management restructuring, consolidating the
PLIVA U.S. operations into Barr, divesting non-strategic operations in
Spain and Italy, completing the IPO of our non-strategic Veterina business,
and expanding our presence in the significant German specialty
pharmaceutical market with the acquisition of O.R.C.A.pharm in September
2007. We reported the highest revenues in our history for our generic oral
contraceptive and proprietary portfolios, with proprietary sales led by
sales of Plan B(TM) and ParaGard(R). We also initiated a record 11 U.S.
patent challenge cases, and completed the patent challenge trial related to
the Yasmin(R) oral contraceptive. Individually, these accomplishments
represent the core strengths of our business. Combined, they speak to the
significant opportunities the combination of Barr and PLIVA has created for
long-term growth and success."
Generic Product Sales
Sales of the Company's generic products were $506 million in the fourth quarter of 2007 and $1.9 billion for 2007, both reflecting significant increases over the prior year periods mainly due to the PLIVA acquisition. A discussion of the Company's generic product sales for the fourth quarter of 2007 compared to the prior year period is presented below.
U.S. Generic Sales
Sales of U.S. generic products totaled $310 million for the fourth quarter of 2007, compared to $298 million in the prior year period. The increase in sales is primarily related to the full quarter impact of sales of PLIVA's U.S. product line in 2007, including Azithromycin. These products are now being sold under the Barr label.
Sales of generic oral contraceptives,
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved